Monoclonal Antibodies Specific for Human IgE-Producing B Cells: A Potential Therapeutic for IgE-Mediated Allergic Diseases

  title={Monoclonal Antibodies Specific for Human IgE-Producing B Cells: A Potential Therapeutic for IgE-Mediated Allergic Diseases},
  author={Tse Wen Chang and Frances M. Davis and N. C. Sun and Cecily R. Y. Sun and Donald W MacGlashan and Robert G. Hamilton},
Monoclonal antibodies (MAbs) specific for surface antigens of lymphocytes are being used to target and deplete tumorous or normal lymphocytes in vivo. Here, we report evidence for the existence of antigenic epitopes on IgE that are accessible on IgE-secreting B cells but not on other cells bearing IgE. Among 42 murine MAbs specific for human IgE, two were shown by fluorescence flow cytometric analyses to bind to IgE-secreting cell lines but not to IgE bound to high-affinity IgE. Fc receptors… 
Anti-IgE Agents
The development of drugs that interfere with IgE production and function may represent a more specific approach to treat these pathological conditions.
IgE-dependent signaling as a therapeutic target for allergies.
Monoclonal Antibodies against the CεmX Domain of Human Membrane-Bound IgE and Their Potential Use for Targeting IgE-Expressing B Cells
The study was designed to evaluate the effects of CΕmX-specific monoclonal antibodies (mAbs) to target IgE-expressing B cells and decrease IgE production and revealed that mAbs are able to cause complement-mediated cytotoxicity on transfectants expressing the Fc portion of mIgE.
Humanized Anti-IgE mAb Hu-901 Prevents the Activation of Allergen-Specific T Cells
Data clearly indicate that anti-IgE antibodies for the treatment of allergy exert their effect not only by inhibiting mast cell/basophil degranulation, but also by preventing T cell activation, which possibly explains the effect of anti- IgE treatment on late-phase reactions noted in clinical studies.
Therapeutic potential of anti-IgE antibodies.
Anti-IgE as a mast cell-stabilizing therapeutic agent.
  • T. Chang, Y. Shiung
  • Biology, Medicine
    The Journal of allergy and clinical immunology
  • 2006
Epitope-specific antibody response to IgE by mimotope immunization.
It is concluded that mimotopes or mimotope-derived peptides might be used for vaccination to induce in vivo a beneficial anti-IgE response as a novel immunotherapy.
A specific feedback by anti-IgE autoantibodies on the cytokine network in allergy.
A theoretical model implying that anti-IgE autoantibodies are specific feed back molecules that neutralize IgE induced by the cytokine network is proposed.


Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1.
Results indicate an important physiologic role for BSF-1 in the generation of IgE antibody responses and suggest means for limiting the production of antibodies responsible for allergic reactions without inhibiting protective antibody responses.
IgE-binding factors and regulation of the IgE antibody response.
  • K. Ishizaka
  • Biology, Medicine
    Annual review of immunology
  • 1988
If the same procedures would be effective for human T cells of allergic patients, it would be possible to generate antigen-specific suppressor T cells from their T cell population in vitro and to establish T cell hybridomas that produce allergen-specific GIF(TsF).
Relationships between epitopes on IgE recognized by defined monoclonal antibodies and by the FC epsilon receptor on basophils.
Findings establish mAb 51.3 as a useful tool for isolating the IgE peptides involved in the binding site to the receptor, after analysis of the stoichiometry and affinity binding of 125I anti-IgE mAb Fab' to free IgE.
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
It is shown here that unmodified monoclonal antibodies can be extremely effective at depleting cells in vivo and can be used for the selective manipulation of different aspects of the immune response.
The B-cell binding site on human immunoglobulin E
FcσR2 can recognize a motif in the Cσ3 domain that is formed on dimerization of one or both of the flanking domains, and Glycosylation of IgE is not required for the activity of either receptor.
In vitro reversed anaphylaxis: characteristics of anti-IgE mediated histamine release.
Leucocytes from allergic and most normal human donors release histamine when challenged with antibodies against human γ-globulin, and data suggest that cell bound IgE is of major importance in the in vitro anaphylactic response and that the direct and reversed in vitroAnaphylaxis reactions both operate through cell-bound IgE and share a common reaction mechanism.
A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma.
The addition of concanavalin A-stimulated supernatants of the helper T cell clone, D9.1, to cultures of lipopolysaccharide (LPS)-stimulated T-depleted mouse spleen cells caused more than a 100-fold
Clonal and molecular characteristics of the human IgE-committed B cell subset
It is proposed that IgE-committed cells represent a unique B cell sublineage whose differentiation pathway may be more strictly regulated than that of other isotypes with regard to the signals required for classical, deletional switch recombination that has been observed in rare Ig E-producing myeloma cell lines.